重组抗人 CD22嵌合抗体 SM03的 125 I标记及生物活性

路萍萍, 孟志云, 吴英良, 王敏伟, 窦桂芳

路萍萍, 孟志云, 吴英良, 王敏伟, 窦桂芳. 重组抗人 CD22嵌合抗体 SM03的 125 I标记及生物活性[J]. 同位素, 2008, 21(1): 20-24. DOI: 10.7538/tws.2008.21.01.0020
引用本文: 路萍萍, 孟志云, 吴英良, 王敏伟, 窦桂芳. 重组抗人 CD22嵌合抗体 SM03的 125 I标记及生物活性[J]. 同位素, 2008, 21(1): 20-24. DOI: 10.7538/tws.2008.21.01.0020
Bioactivity assays and application of 125I radiolabeled human mouse chimeric anti-CD22 monoclonal antibody, SM03[J]. Journal of Isotopes, 2008, 21(1): 20-24. DOI: 10.7538/tws.2008.21.01.0020
Citation: Bioactivity assays and application of 125I radiolabeled human mouse chimeric anti-CD22 monoclonal antibody, SM03[J]. Journal of Isotopes, 2008, 21(1): 20-24. DOI: 10.7538/tws.2008.21.01.0020

重组抗人 CD22嵌合抗体 SM03的 125 I标记及生物活性

详细信息
    通讯作者:

    路萍萍

Bioactivity assays and application of 125I radiolabeled human mouse chimeric anti-CD22 monoclonal antibody, SM03

  • 摘要: 摘要: 目的 探讨采用125I标记的重组抗人CD22嵌合抗体SM03的生物活性测定以及应用。方法 将单克隆抗体SM03用Iodogen法标记,用Sephacryl S-300 HR色谱主分离标记混合物,测定分离后样品的纯度与浓度。采用竞争结合法和酶联免疫吸附法(ELISA)测定纯化后样品的活性。最后用标记后的SM03筛选CD22抗原表达量最多的细胞。结果 抗体经过放射性标记后纯度>99%,回收率>67%。125I-SM03的生物活性与未标记抗体没有显著性差异。在Raji,Daudi和Ramos细胞中,SM03与Ramos细胞的特异性结合量最多,结合量为1.3 pmol/细胞。结论 Indogen法可以用于单克隆抗体SM03的标记,标记后不会影响抗体的活性。证明了标记后的SM03具有应用价值。
    Abstract: Abstract: AIM To investigate the bioactivity and application of 125I radiolabed human mouse chimeric monoclonal SM03. METHODS: SM03 was radiolabeled with Indogen method. The radiolabled mixture was purified by Sephacryl S-300 HR separation chromospectry. We determined the purity and concentration of separated fraction. The radiolabeled SM03 was applied to screen which cell line express maximum CD22 antigen. RESULTS: The purity and recovery of radiolabeled SM03 were >99% and >47%, respectively. The bioactivity of 125I labeled SM03 and non-labeled SM03 did not have significant difference in statistics. Ramos cell line had the strongest special radioactivity when bound with SM03 in Raji, Daudi and Ramos cell lines. CONCLUSION: Human mouse chimeric anti-CD22 monoclonal antibody can be radiolabeled with Indogen method. The radiolabel will not affect the activity of SM03.
  • [1] CESANO A, GAYKO U, BRANNAN C, et al. Differential Expression of CD22 in Indolent and Aggressive Non Hodgkin's Lymphoma: Implications for Targeted Immunotherapy[J].Blood, 2002, 100: 350.
    [2] YANG L, LI DF, FENG XY,et al. Construction andCharacterization of Recombinant Anti B lymphoma Chemeric Antibody[J]. Chinese Journal of New Drugs, 2006, 15(3):186 192
    [3] van HORSSEN PJ, van OOSTERHOUT Yv Jm, WITTET DE, et al.Cytotoxic Potency of CD22 Ricin A Depends on Intracellular Routing Rather than on the Number of Internalized Molecules[J]. Scandinavian J Immunology, 1995, 41 (6): 563 569.
    [4] CATCHARD G. The Attraction of Proteins for Small Molecules and Ions[J]. Ann NY Acad Sci 1991, 51: 660 672
    [5] HU Ruihai, ZHANG Ying, ZHAO Minghui. Tr ansferrin Receptor and Fc α /μ Receptor MayNot Be the Major IgA1 Receptor on Human Mesangial Cells[J]. Chinese Medical Journal, 2005, 118(9): 781 785
    [6] ROSSMANN ED, LUNDIN J, LENKEI R, et al. Variability in B cell Antigen Expression: Implications for the Treatment of B Cell Lymphomas and Leukemias With Monoclonal Antibodies[J]. Hematol J, 2001, 2(5): 300 306
计量
  • 文章访问数:  849
  • HTML全文浏览量:  0
  • PDF下载量:  1635
  • 被引次数: 0
出版历程
  • 收稿日期:  2007-05-29
  • 修回日期:  2007-12-23
  • 刊出日期:  2008-02-19

目录

    /

    返回文章
    返回